Actinium Pharmaceuticals, Inc. (ATNM): Nasdaq/NYSE listing notice — Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26

Actinium Pharmaceuticals, Inc.

Stockholders' equity $2.3M as of March 31, 2026, below NYSE American's $4M minimum; net losses in last 5 fiscal years.
Must submit compliance plan by June 26, 2026; deadline to regain compliance by November 27, 2027.
Company announced three ATNM-400 presentations at SNMMI 2026 (May 31-June 2) showing preclinical data in prostate cancer and NSCLC.
If plan not accepted or compliance not regained, delisting proceedings will commence; no immediate effect on trading.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Actinium Pharmaceuticals, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii), 1003(a)(iii)).

Exchange: nyse american
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 1003(a)(ii), 1003(a)(iii)

Exact text from the filing

May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company reported stockholders’ equity of approximately

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Actinium Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-062935

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.